Floatz logo

Dapagliflozin

Stroke, Ischemic

Jaime Daniel MondragonSmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

211 Active assets in the Stroke, Ischemic cohort.

Asset / SponsorPhaseRating
Ticagrelor
Sichuan Provincial People's Hospital
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Compound Edaravone
Nanfang Hospital, Southern Medical University
Phase 4BBB
Argatroban
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
3-N-BUTYLPHTHALIDE
Nanfang Hospital, Southern Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Dapagliflozin is also rated in:

type 2 diabetes mellitusDormant
BBB
Indicative ·
78 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
77 / 100
View asset →
arteriosclerosis disorderDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →